SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 9/20/2017 11:51:55 PM - Followers: 153 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
IDRA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Current Report Filing (8-k) 09/11/2017 08:01:47 AM
IDRA News: Notice of Effectiveness (effect) 09/11/2017 06:02:12 AM
IDRA News: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating a... 09/10/2017 07:15:00 AM
IDRA News: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Ind... 09/08/2017 07:30:00 AM
IDRA News: Securities Registration Statement (simplified Form) (s-3/a) 09/08/2017 06:03:09 AM
PostSubject
#2999   Is this it, or does this retrace tag Citrati 09/20/17 11:51:55 PM
#2998   Another high. :-D Citrati 09/19/17 12:06:28 PM
#2997   And again today. :-D Citrati 09/18/17 09:42:38 AM
#2996   https://seekingalpha.com/article/4107278-idera-pharmaceuticals-esmo-winner-buy?a Citrati 09/15/17 02:09:05 PM
#2995   Looking good (GREEN) today! :-D $IDRA Cbdpotential 09/15/17 01:56:38 PM
#2994   Mojo has returned after testing 13ema. Citrati 09/15/17 10:24:03 AM
#2993   * * $IDRA Video Chart 09-12-17 * * ClayTrader 09/12/17 04:31:11 PM
#2992   You got your wish. I sold half Stockdoggy 09/12/17 04:01:59 PM
#2991   Gap filled rebought. Citrati 09/12/17 03:44:36 PM
#2990   * * $IDRA Video Chart 09-11-17 * * ClayTrader 09/11/17 04:52:53 PM
#2989   https://seekingalpha.com/article/4105817-idera-pharmaceuticals-idra-presents-imo Citrati 09/11/17 02:06:03 PM
#2988   I should have bought so much more! $idra Never go Cbdpotential 09/11/17 10:34:53 AM
#2987   Yep, Congrats. :-D Citrati 09/11/17 09:29:52 AM
#2986   Nice! $IDRA GREEN ... Follow the science ;-) Patience And Perspective Cbdpotential 09/11/17 08:44:54 AM
#2985   Great results out this morning with IMO-2125 with Stockdoggy 09/11/17 07:07:14 AM
#2984   Where have I heard that? Rarely do I kld2 09/08/17 10:07:22 AM
#2983   Perceived strength can sometimes be nothing more than ohsaycanyousee82 09/08/17 09:09:54 AM
#2982   Everyone just hoping and praying for an adjusted ohsaycanyousee82 09/08/17 09:05:57 AM
#2981   I agree Looking good here imo $idra Cbdpotential 09/08/17 08:40:52 AM
#2980   Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment Cbdpotential 09/08/17 08:39:59 AM
#2979   looks like Milano is setting things up nicely kld2 09/08/17 07:59:21 AM
#2978   So far so GREEN :-D Cbdpotential 09/07/17 12:51:11 PM
#2977   Looks like price has survived the pullback test Citrati 09/07/17 12:47:41 PM
#2976   September ~11th seems to be a major day(s) Cbdpotential 09/06/17 04:55:00 PM
#2975   That would be nice! attilathehunt 09/02/17 05:43:31 PM
#2974   I'm hoping this bounces back over 1.90 next Cbdpotential 09/01/17 04:00:43 PM
#2973   Still Green. :-D Citrati 09/01/17 02:22:54 PM
#2972   Posted this on YMB and Stocktwits. Bob Doody kld2 08/31/17 03:10:54 PM
#2971   ESMO abstract out. 6/9 on 8mg had clinical kld2 08/30/17 08:19:38 PM
#2970   2 dolla holla $IDRA Looking good Stay GREEN everyone :-D Cbdpotential 08/30/17 01:05:21 PM
#2969   I'm watching. I like the strength it's showing kld2 08/29/17 01:17:35 PM
#2968   Chart and price performing nicely and not a Citrati 08/28/17 02:41:33 PM
#2967   Going after the 50 day and resistance again. Citrati 08/24/17 01:47:39 PM
#2966   Yep, :-D Citrati 08/17/17 12:29:42 AM
#2965   So many great deals rn ... This is one Cbdpotential 08/11/17 02:44:01 PM
#2964   Closed right between them. Those bots sure Citrati 08/08/17 05:27:27 PM
#2963   Well that was an early smack down. Citrati 08/08/17 09:46:18 AM
#2962   Stuck going sideways in the support/resistance zone of Citrati 08/07/17 03:13:08 PM
#2961   Doing a great job so far building a Citrati 08/04/17 02:27:05 PM
#2960   A solid CC and understanding with report on Citrati 08/03/17 09:45:33 AM
#2959   Currently hanging on to the the mid Citrati 08/02/17 10:03:31 AM
#2958   Using market as opportunity for IDRA to test Citrati 07/27/17 02:23:52 PM
#2957   It is all about march 2.10 now. Citrati 07/25/17 10:30:24 AM
#2956   Market structure and all ma's are on our Citrati 07/25/17 10:01:32 AM
#2955   Looking good Would love to see this hold over Cbdpotential 07/25/17 09:44:01 AM
#2954   No doubt I'm more optimistic than ever $idra Cbdpotential 07/24/17 02:44:43 AM
#2953   Well, IDRA still has some perky in it. Citrati 07/20/17 04:23:33 PM
#2952   No joke Cbdpotential 07/15/17 08:20:59 PM
#2951   Agreed. I've been holding for a couple of Phantom Lord 07/12/17 07:06:34 PM
#2950   Thanks Citrati! Let's hope our other baby attilathehunt 07/12/17 07:04:33 PM
PostSubject